BBT-176
- Generic Name
- BBT-176
Phase 1/2 Study of BBT-176 in Advanced NSCLC With Progression After EGFR TKI Treatment
- First Posted Date
- 2021-03-29
- Last Posted Date
- 2023-12-14
- Lead Sponsor
- Bridge Biotherapeutics, Inc.
- Target Recruit Count
- 45
- Registration Number
- NCT04820023
- Locations
- 🇰🇷
Seoul National University Bundang Hospital, Seongnam-si, Gyeonggi-do, Korea, Republic of
🇰🇷Severance Hospital, Seoul, Korea, Republic of
🇰🇷Samsung Medical Center, Seoul, Korea, Republic of
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath